BioPlus Acquisition priced its upsized IPO of 20 million units at $10 each, an increase of 2 million units registered in an amended S-1 filing last month, but down from the 22 million units initially registered in July for the offering.
Units begin trading today on the Nasdaq under BIOSU. Each consists one Class A share and one-half of a warrant.
BioPlus intends to focus its search on companies in the life sciences industry.
Cantor Fitzgerald is sole book-running manager for the offering. Read more.
